Abstract:Human papillomavirus (HPV) vaccines based on HPV L1 virus-like particles (VLPs) are already licensed but not accessible worldwide. About 38.0 million people were living with HIV in 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against both viruses are an urgent need. In this study, the HIV-1 P18I10 CTL peptide from the V3 loop of HIV-1 gp120 glycoprotein was inserted into the HPV16 L1 protein to construct chimeric HPV:HIV (L1:P18I10) VLPs. Instead of the traditional baculovirus expression vector/insect cell (BEVS/IC) system, we established an alternative mammalian 293F cell-based expression system using cost-effective polyethylenimine-mediated transfection for L1:P18I10 protein production. Compared with conventional ultracentrifugation, we optimized a novel chromatographic purification method which could significantly increase L1:P18I10 VLP recovery (~56%). Chimeric L1:P18I10 VLPs purified from both methods were capable of self-assembling to integral particles and shared similar biophysical and morphological properties. After BALB/c mice immunization with 293F cell-derived and chromatography-purified L1:P18I10 VLPs, almost the same titer of anti-L1 IgG (p = 0.6409) was observed as Gardasil anti-HPV vaccine-immunized mice. Significant titers of anti-P18I10 binding antibodies (p < 0.01%) and P18I10-specific IFN-γ secreting splenocytes (p = 0.0002) were detected in L1:P18I10 VLP-immunized mice in comparison with licensed Gardasil-9 HPV vaccine. Furthermore, we demonstrated that insertion of HIV-1 P18I10 peptide into HPV16 L1 capsid protein did not affect the induction in anti-L1 antibodies. All in all, we expected that the mammalian cell expression system and chromatographic purification methods could be time-saving, cost-effective, scalable platforms to engineer bivalent VLP-based vaccines against HPV and HIV-1.

Stable High-Level Expression of Truncated Human Papillomavirus Type 16 L1 Protein in Drosophila Schneider-2 Cells.

Construction, Expression, Purification and Identification of Chimeric HPV16 E7-L1 Virus Like Particles

Production of human papillomavirus type 16 virus-like particles and its immunogenicity]

Highly Efficient and Economical Baculovirus Expression System for Preparing Human Papillomavirus Type16 Virus-like Particle

Functional HPV16L1 VLP can be efficiently expressed by His-tag baculovirus expression system

Human Papillomavirus L1 Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles That Are Highly Immunogenic.

[Carboxyl Terminus Truncated HPV58 Virus L1 Protein Expressed with Baculovirus System and Its Bioactivity].

Development a scalable production process for truncated human papillomavirus type-6 L1 protein using WAVE Bioreactor and hollow fiber membrane

Preparation and biological activity of human papillomavirus type 52 virus-like particles

Construction and identification of drosophila expression vector of protein L1 gene of human papillomavirus type 18

Recombinant Expression of Truncated Human Papillomavirus 58 L1 Protein with Molecular Chaperones in E.coli

[Expression, Purification and Immunogenicity Analysis of HPV Type 18 Virus-Like Particles from Escherichia Coli].

Expression of human papillomavirus type16 late gene (L1) in prokaryotic cells and its immune effict observation

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

[Cloning and Expressing of Human Papillomavirus 16 E7C Subgene].

Assembly and Immunogenicity of Human Papillomavirus Type 16 Major Capsid Protein(Hpv16 L1) in Pichia Pastoris

Expression of Human Papillomavirus Type 16 L1 Protein in Transgenic Tobacco Plants

Increasing the expression levels of papillomavirus major capsid protein in Escherichia coli by N-terminal deletion.

[Prokaryotic Expression of HPV 16 L1 Gene and Identification of Its Immune Activity].

Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice

Engineering of Recombinant Human Papillomavirus 16 L1 Protein for Incorporation with para-Azido- L-Phenylalanine